News & Events

Corporate Presentation

Corporate Presentation - September 2019

News Releases

Year

Stemline Therapeutics to Present at the Ladenburg Thalmann 2019 Healthcare Conference

September 18, 2019

NEW YORK , Sept. 18, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that Ivan Bergstein , M.D., Stemline’s CEO, will present at the

Additional Formats

PDF Version

Stemline Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference

September 5, 2019

NEW YORK , Sept. 05, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that Ivan Bergstein , M.D., Stemline’s CEO, will present at the

Additional Formats

PDF Version

Stemline Therapeutics to Present at the 2019 Wedbush PacGrow Healthcare Conference

August 9, 2019

NEW YORK , Aug. 09, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that Ivan Bergstein , M.D., Stemline’s CEO, will present at the 2019

Additional Formats

PDF Version

Stemline Therapeutics Announces Pricing of $76,250,000 Public Offering of Common Stock

August 8, 2019

NEW YORK , Aug. 08, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc . (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing innovative oncology therapeutics, today announced the pricing of an underwritten public offering

Additional Formats

PDF Version

Stemline Therapeutics Announces Proposed Public Offering of Common Stock

August 7, 2019

NEW YORK , Aug. 07, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) , a commercial -stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing innovative oncology therapeutics, today announced that it intends to offer and sell, subject to

Additional Formats

PDF Version